Advanced Accelerator Applications S.A. develops, produces, and commercializes radiolabeled pharmaceuticals and diagnostic nuclear medicines in France and internationally. It provides positron emission tomography (PET) products, including Gluscan, a branded 18-fluorodeoxyglucose PET imaging agent that assists in the diagnosis of oncology through assessing glucose metabolism; DOPAVIEW, a PET tracer for diagnostic use with applications in neurology and oncology sectors; and FluoroChol, a PET tracer for detecting metastasis of prostate cancer and hepatocellular carcinoma. The company also offers single-photon emission computed tomography (SPECT) products comprising Tetrakis (2-methoxyisobutyl isonitrile) copper (I) tetrafluoroborate, a cardiac imaging agent for myocardial exploration, localization of parathyroid tissue, and breast cancer diagnosis; and Leukokit, a single-use medical device to carry out separation and labeling of autologous leukocytes. In addition, it offers NETSPOT, a kit for the preparation of gallium Ga 68 dotatate injection for the localization of somatostatin receptor positive neuroendocrine tumors in adult and pediatric patients using PET; SomaKit TOC, a kit for radiopharmaceutical preparation of gallium edotreotide solution; and Annexin V-128, a SPECT radiopharmaceutical product candidate for the imaging of apoptotic and necrotic lesions. Its products that are in clinical development comprise Lutathera, a Lu-177 labeled somatostatin analogue peptide that has been approved for the treatment of neuro endocrine tumors; PSMA-R2, a selective PSMA-targeted ligand for prostate cancer; and NeoBOMB1, an antagonist bombesin analogue targeting GRPR-expressing malignancies. The company was founded in 2002 and is headquartered in Saint Genis Pouilly, France. As of January 31, 2018, Advanced Accelerator Applications S.A. operates as a subsidiary of Novartis Groupe France S.A. more
| Time Frame | AAAP | S&P500 |
|---|---|---|
| 1-Week Return | - | -1.8% |
| 1-Month Return | - | -2.08% |
| 3-Month Return | - | 11.56% |
| 6-Month Return | - | 6.43% |
| 1-Year Return | - | 20.72% |
| 3-Year Return | - | 69.79% |
| 5-Year Return | - | 71.71% |
| 10-Year Return | -10.96% | 269.13% |
| Sector | Weight |
|---|---|
|
Health Care
|
100.00% |
Advanced Accelerator Applications S.A (AAAP) share price today is $25.076.
Yes, Indians can buy shares of Advanced Accelerator Applications S.A (AAAP) on Vested. To buy AAAP from India, you can open a US Brokerage account by signing up on Vested. The account opening process is completely digital and secure, and takes 3-5 minutes to complete.
Yes, you can purchase fractional shares of Advanced Accelerator Applications S.A (AAAP) on Vested. You can start investing in Advanced Accelerator Applications S.A (AAAP) with a minimum investment of $1.
The 52-week high price of Advanced Accelerator Applications S.A (AAAP) is $. The 52-week low price of Advanced Accelerator Applications S.A (AAAP) is $.
The stock symbol (or ticker) of Advanced Accelerator Applications S.A is AAAP.
Yes, you can setup SIP in Advanced Accelerator Applications S.A shares. Follow the below steps to create the SIP:
Here is the historical performance of AAAP on the Vested app.
The expense ratio of Advanced Accelerator Applications S.A (AAAP) is .
Link copied
